In the latest trading session, Gilead Sciences (GILD) closed at $88.08 ... The HIV and hepatitis C drugmaker's stock has climbed by 5.87% in the past month, exceeding the Medical sector's loss ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Shares of Gilead Sciences Inc. GILD shed 0.73% to $86.72 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.40% to 5,864.67 ...

(RTTNews) - Gilead Sciences Inc. (GILD) announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of ...

Gilead Sciences (GILD) closed the latest trading ... The HIV and hepatitis C drugmaker's stock has climbed by 5.22% in the past month, exceeding the Medical sector's loss of 4.16% and the S ...

In this piece, we will look at where Gilead Sciences, Inc. (NASDAQ ... and it covered the bank’s thoughts about the stock market and the US economy for September. The other came in October ...

Truist Financial increased their price target on Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Sanford C. Bernstein assumed ...

Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period. The most recent guidance for Gilead ...

Leerink has upgraded Gilead Sciences (NASDAQ:GILD ... see more potential for stock upside with these catalysts,” it added. The investment firm raised its price target to $96 from $74.